Pembrolizumab Approval in Squamous NSCLC Expands Treatment Arsenal
Published: Friday, May 17, 2019
Viola W. Zhu, MD, PhD
Platinum-doublet chemotherapy is no longer standard of care for patients with advanced squamous non–small cell lung cancer (NSCLC) following the results of the KEYNOTE-407 trial, which demonstrated an improvement in progression-free survival (PFS) and overall survival (OS) irrespective of PD-L1 expression, explained Viola W. Zhu, MD, PhD.
... to read the full story